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Abstract
Objective. Assessment of disease activity in vasculitis can be achieved using the BVAS, a clinical check-
list of relevant symptoms, signs and features of active disease. The aim of this study was to revalidate the
BVAS version 3 (BVAS v. 3) in a cohort of patients with systemic vasculitis.
Methods. A total of 238 patients with vasculitis from seven countries in Europe were evaluated at a single
time point. Spearman’s correlation coefficients were calculated between BVAS v. 3 scores, vasculitis
activity index (VAI), physician’s global assessment (PGA), the physician’s treatment decision, CRP and
the vasculitis damage index (VDI) to demonstrate that the BVAS v. 3 measures disease activity.
Results. WG (63%), ChurgStrauss syndrome (9%) and microscopic polyangiitis (9%) were the most
common diagnoses. The BVAS v. 3 showed convergent validity with the VAI [= 0.82 (95% CI 0.77,
0.85)], PGA [= 0.85 (95% CI 0.81, 0.88)] and the physician’s treatment decision [= 0.54 (95% CI 0.44,
0.62)]. There was little or no correlation between BVAS v. 3 and the CRP level [= 0.18 (95% CI 0.05,
0.30)] or with the VDI [=0.10 (95% CI 0.22, 0.03)]. The inter-observer reliability was very high with an
intra-class correlation coefficient (ICC) of 0.996 (95% CI 0.990, 0.998) for the total BVAS v. 3 score.
Conclusion. The BVAS v. 3 has been evaluated in a large cohort of patients with vasculitis and the
important properties of the tool revalidated. This study increases the utility of the BVAS v. 3 in different
populations of patients with systemic vasculitis.
Key words: Disease activity, Outcomes research, Systemic vasculitis, Vasculitis, Wegener’s granulomatosis.
Introduction
The vasculitides are a group of complex heterogeneous
disorders where multiple organ systems can be involved.
The common feature between these diseases is inflamma-
tion of blood vessels; usually categorized by the predom-
inant calibre of the vessels involved. Most of the
vasculitides can be fatal or organ threatening and require
therapy with CSs alone or in combination with more
potent immunosuppression.
Disease activity is a well-recognized concept for inflam-
matory diseases where high disease activity suggests the
need to escalate treatment and low disease states indi-
cate that the disease is under control with current therapy.
This differs from the concept of damage in vasculitis,
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which represents chronic scarring that is not responsive to
further therapy [1]. Unfortunately, in systemic vasculitis
there is no single biomarker that can reliably inform us
about disease activity. Inflammatory markers such as
CRP are non-specific and may be raised for multiple
other reasons or may be low due to recent steroid treat-
ment. Other assessments such as rising ANCA titres [2],
PET scanning [35] and MRI have all been proposed as
methods of measuring activity but none have yet proved
to satisfactorily perform this function [6, 7]. Instead, the
current best method of determining disease activity is to
use a comprehensive clinical tool that can capture the
multi-organ nature of vasculitis [8].
The importance of accurately quantifying disease activ-
ity is to allow physicians to make informed decisions
about how to manage potentially toxic therapies. The cur-
rent most widely used generic tool to quantify disease
activity in systemic vasculitis is the BVAS [810]. The ori-
ginal version was developed by consensus expert opinion
in 1994 and consisted of 59 items grouped into nine organ
systems [8]. The BVAS was subsequently modified for
use in the European Vasculitis Study Group (EUVAS)
trials [version (v.) 2] [9] and more recently to the current
version: BVAS v. 3 [10]. The main difference between
BVAS v. 3 and v. 2 is that the persistent boxes for each
variable were replaced by a single box for the whole form,
which is only ticked if all the items are due to persistent
disease. There was a reduction in the number of items
from 64 to 56 by merging or omission, but the overall
maximum score was maintained. The weighting of items
that was decided by expert consensus in the original
version has remained relatively unchanged between the
three versions.
The BVAS v. 3 has undergone initial validation in a
cohort of 313 patients with mixed primary and secondary
vasculitis from the UK [10]. The objective of this study was
to revalidate the BVAS v. 3 in a different cohort of patients
from Europe.
Patients and methods
Two hundred and thirty-eight consecutive patients (both
inpatients and outpatients) with new or existing diagnoses
of vasculitis were recruited from 11 centres in 7 European
countries: UK (55), Netherlands (51), Denmark (49),
Germany (47), Italy (25), Czech Republic (6) and Sweden
(5). Local medical ethics requirements were met by each
participating site. Only UK sites required formal ethics
approval. Continental European sites did not require
formal ethical approval as this was an observational
study and did not involve any specific intervention.
Participants gave their written informed consent before
participating in the study. Basic demographics, type of
vasculitis and duration of disease were recorded
(Table 1). All patients were assessed for disease activity
and disease damage.
Disease activity was measured using the BVAS v. 3,
vasculitis activity index (VAI) [11], physician global assess-
ment on a 100-mm visual analogue scale (PGA), treatment
decision (description given in Table 2) and CRP. The VAI is
an alternative validated measure of disease activity, which
incorporates a subjective score for nine organ systems
based on perceived severity of involvement (each organ
scored 04), and then the overall score divided by the
number of organ systems scored [11]. The BVAS v.
3 was tested against alternative measures of disease
activity to assess convergent validity. Convergent validity
tests the extent to which assessments that should
theoretically be related to each other are in fact related.
To demonstrate that BVAS v. 3 does not measure
damage, we tested it against the vasculitis damage
index (VDI), which is a validated measure of damage
in systemic vasculitis. Inter-observer reliability (repro-
ducibility) of BVAS v. 3 was examined in patients inde-
pendently assessed by two observers on the same day
(n= 20).
TABLE 1 Baseline demographics of the revalidation cohort
Diagnosis n (%) F M
Median
age (range),
years
Median disease
duration (range),
months
WG (renal) 98 (41.2) 39 (40) 59 (60) 56 (1785) 38 (1362)
WG (non-renal)a 51 (21.4) 26 (51) 24 (47) 53 (1975) 68 (1269)
ChurgStrauss syndromea 23 (9.7) 12 (52) 10 (43) 68 (4582) 20 (2252)
Microscopic polyangiitis 22 (9.2) 10 (45) 12 (55) 56 (1781) 38 (2219)
Otherb 13 (5.5) 10 (77) 3 (23) 62 (2984) 34 (0228)
Mixed essential cryoglobulinaemiaa 9 (3.8) 7 (78) 1 (11) 56 (2777) 49 (8420)
HscP 7 (2.9) 4 (57) 3 (43) 23 (1978) 18 (2336)
Takayasu arteritis 6 (2.5) 6 (100) 0 (0) 32 (2162) 98.5 (36145)
Behc¸et’s disease 5 (2.1) 3 (60) 2 (40) 39 (2166) 120 (24480)
Leucocytoclastic skin vasculitis 2 (0.8) 1 (50) 1 (50) 55 (2584) 41.5 (578)
Polyarteritis nodosa (Hep B negative) 2 (0.8) 1 (50) 1 (50) 57 (3778) 160 (114206)
aGender was missing for one patient. bOther vasculitis comprised: ANCA-positive vasculitis not fitting any specific diagnosis;
CNS vasculitis; drug-induced vasculitis; Goodpasture’s disease; systemic rheumatoid vasculitis; not further specified; SLE
vasculitis; GCA; hypocomplementaemic urticarial vasculitis.
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Statistical analysis
R version 2.9.1 (26 June 2009), USA was used for
the statistical analysis. The distributions of the BVAS v.
3 scores were not normally distributed, so we used a
non-parametric approach based on ranks to measure its
correlation with the VAI, treatment decision, CRP and
PGA. In instances where more than one observation was
available in a single patient, measurements from the
patient’s first visit were used for correlation.
Spearman’s rank correlation coefficient () was calcu-
lated by independently ranking the two scores, then cal-
culating the Pearson correlation between the ranks rather
than the original measurements. The CIs for  were calcu-
lated using Fisher’s transformation.
We used the intra-class correlation coefficient (ICC) to
calculate inter-observer reliability for the overall BVAS v.
3 score. This method estimates the average correlation
between all possible orderings of pairs, and was calcu-
lated using a one-way analysis of variance (ANOVA). To
assess reliability between observers for each of the cate-
gories in the BVAS v. 3 score, a linear-weighted k-statistic
was calculated, in which observed and expected propor-
tions of agreement are modified to include partial agree-
ments by assigning a weight of between 0 (complete
disagreement) and 1 (complete agreement) to each
category.
Results
The demographics of the cohort are shown in Table 1. WG
(63%), ChurgStrauss syndrome (9%) and microscopic
polyangiitis (9%) were the most common diagnoses. The
remaining patients suffered from a mixture of other pri-
mary and secondary vasculitides. The BVAS v. 3 score
ranged from 0 to 39 (maximum possible score 63) with
the largest range seen in patients with WG. There were
115 patients who were in remission (BVAS v. 3 score of 0)
and 123 patients with active disease (BVAS v. 3
score51). Table 2 compares the range scores for each
diagnosis between this cohort and the original validation
cohort.
Convergent validity
Of 238 patients, 234 (98%) had a treatment decision re-
corded. There was moderate correlation between BVAS v.
3 and treatment decision [= 0.54 (95% CI 0.44, 0.62)]
(Fig. 1). The correlation remained the same when patients
in remission (BVAS v. 3 = 0) were excluded from the ana-
lysis [= 0.54, (95% CI 0.40, 0.65)]. Definitions for the
treatment decisions are given in Table 3. Subgroup ana-
lysis of the 147 patients with WG revealed a similar cor-
relation [= 0.58 (95% CI 0.46, 0.68)]. Of the 238 patients,
217 (91%) had CRP levels recorded on the same day the
BVAS v. 3 score was measured. There was a low correl-
ation between BVAS v. 3 and CRP levels [= 0.18 (95% CI
0.05, 0.30)] (Fig. 1). BVAS v. 3 correlated strongly with the
PGA [= 0.85 (95% CI 0.81, 0.88)] and the VAI (= 0.82,
95% CI 0.77, 0.85); n= 188 for both (Fig. 1). The correl-
ation remained strong when patients in remission (BVAS v.
3 = 0) were excluded from the analysis; BVAS v. 3 with
PGA [= 0.79 (95% CI 0.71, 0.85)] and the BVAS v. 3
with VAI (= 0.75, 95% CI 0.66, 0.82).
Divergent validity
There was no correlation between BVAS v. 3 and a con-
current measure of disease damage (the VDI) [=0.10
(95% CI 0.22, 0.03)] (Fig. 2).
TABLE 2 Comparison of the range of diagnosis and BVAS (v. 3) scores between the current study and the original
validation cohort
Diagnosis
Current study,
patients from Europe (n=238)
Original validation cohort,
patients from the UK (n=313),
Mukhtyar et al. [10]
n (%)
BVAS v. 3 median
score (range) n (%)
BVAS v. 3 median
score (range)
WG (general) 98 (41.18) 1 (036) 101 (32.27) 1 (037)
WG (non-renal) 51 (21.43) 0 (039) 54 (17.25) 0.5 (025)
ChurgStrauss syndrome 23 (9.66) 0 (014) 28 (8.95) 0 (024)
Microscopic polyangiitis 22 (9.24) 2 (022) 15 (4.79) 2 (025)
Othera 13 (5.46) 0 (015) 46 (14.70) 4 (034)
Mixed essential cryoglobulinaemia 9 (3.78) 5 (026) 6 (1.92) 6.5 (024)
HScP 7 (2.94) 1 (013) 10 (3.19) 3.5 (021)
Takayasu arteritis 6 (2.52) 0 (04) 9 (2.88) 0 (02)
Behc¸et’s disease 5 (2.10) 6 (018) 25 (7.99) 2 (019)
Leucocytoclastic skin vasculitis 2 (0.84) 2.5 (23) 9 (2.88) 2 (06)
Polyarteritis nodosa (Hep B negative) 2 (0.84) 0.5 (01) 10 (3.19) 0 (06)
aOther vasculitis comprised: ANCA-positive vasculitis not fitting any specific diagnosis; CNS vasculitis; drug-induced vascu-
litis; Goodpasture’s syndrome; systemic rheumatoid vasculitis; not further specified; SLE vasculitis; GCA; hypocomplemen-
taemic urticarial vasculitis; granulomatous nephritis; PM; SS-related vasculitis.
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FIG. 1 Comparison between potential measures of disease activity and the BVAS v. 3; (A) treatment decision, (B) CRP,
(C) PGA and (D) VAI.
TABLE 3 Treatment decision categories and definitions
Category Treatment decision Definition
6 Major escalation Commencing any immunosuppressive agent, glucocorticoid or plasma-
pheresis, without stopping or reducing the dose of any other treatment
OR
Increasing the dose of glucocorticoid and immunosuppressive agent
5 Continue at major level No change to a therapeutic regimen that includes CYC or biologic
therapy
4 Minor escalation Increasing the dose of immunosuppressive agent or glucocorticoid
3 Continue at minor level No change to a therapeutic regimen that excludes CYC and biologic
therapy
2 Reduction at major level start
at minor level
Reduction or stopping of one or more drugs that includes CYC or
biologic therapy
AND
Commencing another drug
1 Reduction of therapy Reduction or stopping of one or more drugs without increasing or
commencing any other drug
0 No therapy No therapy
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Reliability
The inter-observer reliability (n= 20) was very high with an
ICC of 0.996 (95% CI 0.990, 0.998), for the total BVAS v. 3
score. The k-statistics for the individual organ systems of
BVAS v. 3 for inter-observer reliability demonstrated per-
fect agreement [k= 1.0 (95% CI 1.0, 1.0)] for cutaneous,
mucous, ENT, chest, cardio, abdominal, renal and ner-
vous systems. There was good agreement for general
[k= 0.71 (95% CI 0.29, 0.94)] and mucous membranes
[k= 0.88 (95% CI 0.00, 1.0)], although CIs were wide due
to the small numbers. The k-statistics for the cardiovas-
cular and abdominal systems were not defined because
all items were recorded as absent by both observers in all
20 patients.
Discussion
Quantifying vasculitis disease activity and extent of organ
involvement assists clinical decision making. In the ab-
sence of a suitable biomarker that can quantify disease
activity, a structured clinical tool like the BVAS v. 3 is ne-
cessary. The BVAS provides a standardized measure of
disease activity in clinical trials, and provides a structured
approach for these heterogeneous, multisystem disorders
on which treatment decisions in clinical practice can be
based.
This study reinforces the validity of the BVAS v. 3 and
increases the generalizability of the tool. The original val-
idation study included patients from the UK only [10],
whereas this study includes patients from six other coun-
tries across Europe. The BVAS is a generic tool intended
for all types of vasculitis, but has been used primarily in
assessment of disease activity in ANCA-associated vas-
culitis in clinical trial settings [12].
There is no gold standard for measuring disease activity
in vasculitis, and hence our decision to compare multiple
alternative methods. The BVAS v. 3 correlated well with
the VAI and an informed PGA (PGA performed after com-
pleting the BVAS v. 3 form), which both measured disease
activity at the same time point. In addition, there was only
a moderate correlation between BVAS v. 3 and treatment
decision, which was expected. Treatment decision is
dependent on what has happened to a patient’s disease
activity recently (i.e. serial BVAS scores) rather than at a
single time point. For example, at disease onset, if a pa-
tient has haemoptysis and renal failure their disease would
be considered to be very active and the BVAS score
would be high. The treatment decision would be to start
immunotherapy. If we then determined the patient’s dis-
ease activity 4 weeks later, the haemoptysis and renal
failure may have resolved, and therefore the BVAS score
would be low. The treatment decision at that point would
likely be to continue therapy at a major level because of
the recent high disease activity and the knowledge that if
treatment is reduced too soon the disease may flare.
However, if the BVAS was repeated 6 months later and
the score was still 0, the treatment decision would be
likely to reduce therapy. Due to the cross-sectional
nature of this study, we are unable to directly infer from
our results that the BVAS v. 3 influences treatment
decisions.
The feasibility of the tool has already been confirmed by
earlier versions of the BVAS by their use in clinical trials
involving over a thousand patients (the BVAS v. 3 is a
condensed version of the previous versions) [10, 1318].
All versions of the BVAS have high investigator accept-
ance. The BVAS v. 3 form takes <3 min to complete and
requires minimal training, although training is important to
achieve optimum reliability and reproducibility. A training
manual, complete with practice cases and an on-line cal-
culator are available on the European Vasculitis Study
Group (EUVAS) web site: http://www.vasculitis.org/.
Achieving remission (the total absence of disease),
maintaining remission and reducing the frequency of
flares have been the primary outcome measures in most
therapeutic trials in vasculitis in the past decade [10,
1318]. These endpoints have almost always been
defined in terms of the BVAS score, where remission is
a BVAS score of 0 and a flare is a rise in the BVAS score
from 0. Experts in vasculitis, trial investigators and regu-
latory agencies have accepted the BVAS as the best avail-
able measure of disease activity, which reinforces the
content and construct validity of the tool [19]. In addition,
the BVAS score at baseline has been shown to predict
disease damage that occurs within the first 6 months
[20], which in turn predicts mortality [20, 21].
This study has limitations. It is a cross-sectional study
with few longitudinal data. The study design was not con-
ducive to adequately assessing sensitivity to change. In
the original validation study [10], this exercise was carried
out in 39 patients for whom data were available at 0 and 3
months after introduction of treatment classified as major
escalation. The treatment was expected to reduce
FIG. 2 Comparison of disease activity (BVAS v. 3) with
disease damage (VDI), n= 238.
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disease activity in the majority of patients. The BVAS v. 3
met that expectation in a clinically meaningful and a stat-
istically significant way. This aspect of the BVAS v. 3 can
be reassessed in future controlled clinical trials [18]. A
further limitation of the study is the small number of
patients with large-vessel vasculitis and non-ANCA-
associated medium and small-vessel vasculitides that
were evaluated. We think that it is important to continue
to evaluate patients with these other forms of vasculitis to
add to the utility of the tool for those conditions and allow
for cross-comparison between diseases. There is poten-
tial circularity in using the PGA as one of the reference
standards to evaluate the BVAS v. 3. Investigators in
this study both had expertise in vasculitis care and are
involved with research in this area. As a consequence, it
is probable that the PGA was influenced by completion of
the BVAS v. 3 form. We included the PGA in this study
because it is a well-recognized comparator when de-
veloping or validating disease activity scores in other
rheumatological diseases [2224]. In order to reduce this
potential bias when validating the BVAS v. 3, we used
several alternative methods of assessing disease activity
such as the VAI, CRP and treatment decision.
In summary, this study adds support to the validity of
the BVAS v. 3 and provides data that can be combined
with other studies to continue to refine the tool. The cur-
rent weighting of BVAS items is based on expert opinion
[8, 10]. The next evolution of the BVAS is likely to be in the
form of improving the weighting of individual items based
on available data sets (e.g. cross-sectional studies such
as this and the previous validation study [10], as well as
data from the long-term follow-up of the EUVAS trials
[1417], and the Wegener’s Granulomatosis Etanercept
Trial (WGET) [13]). Mahr et al. [25] have attempted to im-
prove the scoring of an alternative version of the BVAS
designed specifically for WG (BVAS/WG) using the PGA
as the reference standard. This method does not improve
on expert opinion because it uses a subjective physician
score as the reference to reweight items. We would ad-
vocate that objective endpoints are used as the external
anchors to determine new weighting. For example, vari-
ables known to influence rates of remission and relapse,
renal survival, cardiovascular survival and mortality, or
these events themselves could be used. We have previ-
ously published a systematic review exploring these fac-
tors [26].
Rheumatology key messages
. Quantifying disease activity in vasculitis is important
for clinical decision making and research.
. The BVAS v. 3 is a validated practical tool to quan-
tify disease activity in systemic vasculitis.
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